Drug Profile
Research programme: polyketide antibacterials - Isomerase Therapeutics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Biotica Technology
- Class Macrolides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Bacterial-infections in United Kingdom (PO)
- 08 Aug 2011 Polyketide antibacterials programme available for partnering/licensing following completion of preclinical proof-of-concept studies. http://www.biotica.com
- 27 Jan 2011 Early research in Bacterial infections in United Kingdom (PO)